Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India’s Stem Cell Guidelines Mandate Additional Checks

Executive Summary

Draft update to national guidelines factors in additional safeguards and makes it mandatory to establish institutional panels to review stem cell research. Gene editing would be an area of "restrictive" research.

You may also be interested in...



India Proposes Classifying Manipulated Cells And Tissue Products As Drugs

The Indian government is proposing to change the definition of a new drug to include substantially manipulated stem cell and tissue-based therapies.

Deal Watch: GSK Declines Option As Ionis' Inotersen Nears Finish Line

Ionis will file polyneuropathy candidate in US and EU on its own, while GSK de-emphasizes rare diseases. Aclaris buys Confluence in earn-out-heavy deal, and Galena undertakes reverse merger with Sellas.

Editas Competitor CRISPR Therapeutics Hails European Patent Decision

CRISPR Therapeutics says its IP position has been reinforced by the European Patent Office's aim to grant the University of California patent recognition covering CRISPR gene-editing for non-cellular and cellular use.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS121175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel